Academia Sinica

National Taiwan University

Jung-Hsin Lin

Jim-Min Fang

Ting-Rong Chern

Jhih-Bin Chen

Ching-Chow Chen

Tzu-Tang Wei

Chih-Cheng Chen

Yun-Lian Lin

Yijuang Chern

Nai-Kuei Huang

Chun-Jung Lin

Benjamin Pang-Hsien Tu

Hung-Li Wang

Compounds for use in prevention and treatment of neurodegenerative disease and pain are disclosed. In one embodiment of the invention, the compound is selected from the group consisting of N-[(3-halothien-2-yl)methyl]adenosine, N-[(4-halothien-2-yl)methyl]adenosine, and N-[(5-halothien-2-yl)methyl]adenosine. In another embodiment of the invention, the compound is selected from the group consisting of N-[(2-bromothien-3-yl)methyl]adenosine, N-[(4-bromothien-3-yl)methyl]adenosine, N-[(5-bromothien-3-yl)methyl]adenosine N-[(2-chlorothien-3-yl)methyl]adenosine, N-[(4-chlorothien-3-yl)methyl]adenosine, and N-[(5-chlorothien-3-yl)methyl]adenosine. Also disclosed are methods of making and using the same.

Compounds for use in prevention and treatment of neurodegenerative diseases and pain

The present invention provides novel compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds and pharmaceutical compositions for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, and a disease associated with oxidative stress), or inhibiting drug resistance of cancer cells. 

3,5,N-trihydroxy-alkanamide and derivatives: method for making same and use thereof

Disclosed herein are novel compounds of formula (I), and uses thereof. The compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds of Formula (I) for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, or a disease associated with oxidative stress, 

Dual action inhibitors against histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme a reductase

Growing community of inventors

Taipei, Taiwan

Jung-Hsin Lin